New drug combo targets recurrent brain tumors

NCT ID NCT05917145

Recruiting now Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a drug called WSD0628, which blocks a DNA repair protein, given together with radiation therapy for people whose high-grade glioma (a type of brain tumor) has come back after previous treatment. The study aims to find the safest dose and see if the combination can shrink tumors. About 94 adults with recurrent glioblastoma or similar tumors will participate at Mayo Clinic.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: WSD0628 (a drug that blocks a DNA repair protein, making cancer cells more sensitive to radiation)
What this could lead to: If this works, it could point toward a new treatment option for people with recurrent high-grade brain tumors that have come back after standard therapy.
What could go wrong: This is a very early (Phase 0/I) trial with only 94 participants, so it is mainly testing safety and dosing. It may not show strong anti-tumor effects, and side effects from combining the drug with radiation are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

astrocytoma, IDH-mutant, grade 3 glioblastoma IDH-wildtype glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Mayo Clinic in Rochester
RECRUITING

Rochester, Minnesota, 55905, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.